Fc-enhanced anti-CD19 humanized IgG monoclonal antibody (Monjuvi) that induces ADCC/ADCP and apoptosis of B cells.
Fc-enhanced humanized anti-CD19 IgG monoclonal antibody that binds CD19 on B cells and promotes Fcγ receptor–mediated ADCC and ADCP, leading to apoptosis and depletion of malignant B cells.
NO
INDIRECT
Tafasitamab binds CD19 on B cells; its Fc engages FcγRIIa (CD32A) on effector cells to mediate ADCC/ADCP that kills CD19+ cells. Cells expressing FcγRIIa are not targeted or killed by the drug.
Fc-enhanced anti-CD19 humanized IgG monoclonal antibody (Monjuvi) that induces ADCC/ADCP and apoptosis of B cells.
Fc-enhanced humanized anti-CD19 IgG monoclonal antibody that binds CD19 on B cells and promotes Fcγ receptor–mediated ADCC and ADCP, leading to apoptosis and depletion of malignant B cells.
NO
INDIRECT
Tafasitamab binds CD19 on B cells; its Fc engages Fcγ receptors (including CD64) on effector cells to trigger ADCC/ADCP that kills CD19+ B cells. CD64+ cells are effectors, not targets, and are not killed by the drug.
A fully human IgG1 anti-CD20 monoclonal antibody (brand name Kesimpta) that binds a distinct epitope on CD20 on mature B cells, inducing rapid and sustained B-cell depletion primarily via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, with possible direct apoptosis; spares hematopoietic stem cells and plasma cells.
Fully human IgG1 anti‑CD20 monoclonal antibody that binds a distinct epitope on mature B cells and depletes them primarily via complement‑dependent cytotoxicity (CDC) and antibody‑dependent cellular cytotoxicity (ADCC), with possible direct apoptosis; spares hematopoietic stem cells and plasma cells.
YES
DIRECT
Ofatumumab binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC; it may also trigger direct apoptosis of the targeted cells.
Subcutaneous T-cell–redirecting bispecific antibody (CD3xCD20) that binds CD3 on T cells and CD20 on B cells to bring them into proximity, activating T-cell cytotoxicity to lyse lymphoma cells.
Bispecific antibody that binds CD3 on T cells and CD20 on B cells, bringing them into proximity to activate and redirect T-cell cytotoxicity to lyse CD20+ B-cell lymphoma cells.
NO
INDIRECT
Epcoritamab binds CD3 on T cells to activate and redirect them to CD20+ B cells; the activated T cells kill the CD20-expressing cells (perforin/granzyme), not the CD3+ T cells.
Subcutaneous T-cell–redirecting bispecific antibody (CD3xCD20) that binds CD3 on T cells and CD20 on B cells to bring them into proximity, activating T-cell cytotoxicity to lyse lymphoma cells.
Bispecific antibody that binds CD3 on T cells and CD20 on B cells, bringing them into proximity to activate and redirect T-cell cytotoxicity to lyse CD20+ B-cell lymphoma cells.
YES
DIRECT
Epcoritamab bridges CD3 on T cells and CD20 on target cells, activating T cells to form an immune synapse and kill CD20+ cells via perforin/granzyme-mediated cytotoxicity.